Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume

Journal of Urology

Volumn 163, Issue 1, 2000, Pages 119-126

  Stamey, Thomas A ^a,b   Yemoto, Cheryl E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biopsy; Prostate; Prostate specific antigen; Prostatic neoplasms; Sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0033992457     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67986-4     Document Type: Article

References (33)

1. Myrtle, J. F., Klimley, P. G., Ivor, L. P. et al: Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. In: Advances in Cancer Diagnostics, 1-6. San Diego: Hybritech, Inc., 1986.
2. 1-antichymotrypsin. Clin Chem, 37: 1618, 1991.
3. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51: 222, 1991.
4. Prestigiacomo, A. F., Chichibu, K., Kuroe, K. et al: Serum PSA assays should be based on PSA-ACT complex to improve the specificity for diagnosing benign prostatic hyperplasia (BPH). J Urol. part 2, 157: 366, abstract 1431, 1997.
5. Catalona, W. J., Smith, D. S. and Ornstein, D. K.: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 277: 1452, 1997.
6. Catalona, W. J., Partin, A. W., Slawin, K. M. et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279: 1542, 1998.
7. Catalona, W. J., Richie, J. P., Ahmann, F. R. et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 151: 1283, 1994.
8. Metz, C. E.: Basic principles of ROC analysis. Semin Nucl Mod, 8: 283, 1978.
9. Prestigiacomo, A. F., Lilja, H., Pettersson, K. et al: A comparison of the "free" fraction of serum prostate specific antigen (PSA) in men with benign and cancerous prostates: the "best case" scenario. J Urol, 156: 350, 1996.
10. Prestigiacomo, A. F. and Stamey, T. A.: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol, 157: 189, 1997.
11. Fleshner, N. E., O'Sullivan, M. and Fair, W. R.: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol, 158: 505, 1997.
12. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol, 151: 1571, 1994.
13. Keetch, D. W. and Catalona, W. J.: Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol, 154: 1795, 1995.
14. Levine, M. A., Ittman, M., Melamed, J. et al: Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol, 159: 471, 1998.
15. Vashi, A. R., Wojno, K. J., Gillespie, B. et al: A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol, 159: 920, 1998.
16. Norberg, M., Egevad, L., Holmberg, L. et al: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology, 50: 562, 1997.
17. Wang, X., Brannigan, R. E., Rademaker, A. W. et al: One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol, 158: 1431, 1997.
18. Stamey, T. A., Freiha, F. S., McNeal, J. E. et al: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, suppl., 71: 933, 1993.
19. Carter, H. B., Sauvageot, J., Walsh, P. C. et al: Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol, 157: 2206, 1997.
20. Dietrick, D., McNeal, J. E. and Stamey, T. A.: Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987, 1995.
21. Stamey, T. A., Donaldson, A. N., Yemoto, C. E. et al: Histological and clinical findings in 896 consecutive prostates treated only by radical retropubic prostatectomy from 1988 to 1997: epidemiologic significance of annual changes. J Urol, 160: 2412, 1998.
22. Noldus, J. and Stamey, T. A.: Limitations of serum PSA in predicting peripheral and transition zone cancer volume as measured by correlation coefficients. J Urol, 155: 232, 1996.
23. Brawer, M. K., Meyer, G. E., Letran, J. L. et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology, 52: 372, 1998.
24. Hammerer, P. G., McNeal, J. E. and Stamey, T. A.: Correlation between serum PSA levels and the volume of the individual glandular zones of the human prostate. J Urol, 153: 111, 1995.
25. Chen, Z., Chen, H. and Stamey, T. A.: Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol, 157: 2166, 1997.
26. Kalish, J., Conner, W. H. and Graham, S. D., Jr.: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology, 43: 601, 1994.
27. Maeda, H., Arai, Y., Ishitoya, S. et al: Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol, 158: 2193, 1997.
28. Djavan, B., Zlotta, A. R., Byttebier, G. et al: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol, 160: 411, 1998.
29. Lin, D. W., Gold, M. H., Ransom, S. et al: Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. J Urol, 160: 77, 1998.
30. Terris, M. K., Prestigiacomo, A. F. and Stamey, T. A.: Comparison of prostate size in university and Veterans Affairs Health Care System patients with negative prostate biopsies. Urology, 51: 412, 1998.
31. Prestigiacomo, A. F., Chichibu, K., Kuroe, K. et al: Serum assays should be based on PSA-ACT complex to improve the specificity for diagnosing benign prostatic hyperplasia. J Urol, suppl., 157: 366, abstract 1431, 1997.
32. Altmen, D. G.: Practical Statistics for Medical Research, London: Chapman and Hall, p. 410, 1997.
33. Rittenhouse, H.: Personal communication. San Diego: Hybritech, Inc.